Sr. Leadership

高级领导

• 批准号: 7714404
• 负责人: DONALD L TRUMP
• 金额: $ 13.83万
• 依托单位: ROSWELL PARK CANCER INSTITUTE CORP
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-07-28 至 2013-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7714404
• 关键词: Address; Administrator; American Association of Cancer Research; American Society of Clinical Oncology; Appointment; Association of American Cancer Institutes; Awareness; Basic Science; Biology; Cancer Center Support Grant; Caring; Cell Therapy; Cells; Chairperson; Clinic; Clinical; Clinical Research; Clinical Trials; Comprehensive Cancer Center; Consult; Counseling; Coupling; Daily; Decision Making; Development; Education; Faculty; Foundations; Funding; Genes; Growth; Image; Institutes; Institution; Lead; Leadership; Left; Malignant Neoplasms; Marshal; Mayo Clinic Cancer Center; Medicine; Molecular Genetics; Molecular Target; Names; National Comprehensive Cancer Network; Numbers; Ohio; Operative Surgical Procedures; Outpatients; Parents; Participant; Phase Transition; Play; Population; Population Sciences; Positioning Attribute; Process; Program Development; Program Evaluation; Prostate; Recruitment Activity; Research; Research Institute; Research Personnel; Resource Sharing; Resources; Retirement; Role; Roswell Park Cancer Institute; Series; Services; Strategic Planning; Stress; Therapeutic; Time; Universities; Virginia; Vision; Walkers; Work; anticancer research; base; cancer Biomedical Informatics Grid; cancer prevention; drug discovery; experience; health disparity; member; professor; programs; symposium; therapeutic target; trend

SENIOR LEADERSHIP In March 2007 after 10 years of leading RPCI through significant and successful governance restructuring and programmatic expansion efforts, Dr. David Hohn retired as the President and CEO of Roswell Park Cancer Institute (RPCI). Dr. Hohn maintains a part-time position at RPCI as a senior advisor providing counsel to senior leadership on issues relevant to network development, facilities expansion planning and special projects. In addition, after 30 years of service, Dr. Youcef Rustum will be retiring from his role as Associate Director for Core Resources in the first quarter of 2008. In 2005, as Dr, Hohn and the Board of Directors (BOD) of RPCI began planning for a leadership transition, the possibility that Dr. Trump would succeed Dr. David Hohn as President and CEO and CCSG PI was raised. The BOD consulted both with Roswell Park leadership as well as an external panel of advisors. Based on this analysis, the BOD developed a succession plan for Dr. Trump's transition which began January 1, 2006 with his appointment to Associate Director of the Institute. The final phase of the transition occurred, as planned, on April 1, 2007 when Dr. Trump was named President and CEO. It is important to note that Dr. Trump was originally recruited to RPCI in 2002 as the Associate Director for Clinical Research and Co-leader of the Targeted Therapeutics Program at RPCI, positions he maintained until his the transition in 2006. Coupling Dr. Trump's leadership and experience with the detailed planning and execution of this succession plan has allowed for a smooth and effective transition of RPCI leadership. The change in the RPCI Director (Hohn) and two Associate Directors (Trump and Rustum) brought new senior leadership opportunities. With Dr. Trump's transition in 2006 to Associate Director of the Institute, Dr. Alex Adjei was recruited from the Mayo Clinic and appointed to the Associate Director for Clinical Research position. He is also the Chair for the Department of Medicine. Dr. Adjei brings a wealth of scientific and administrative leadership experience in cancer clinical research and will also lead the Molecular Targets and Experimental Therapeutics Program. Similarly, with Dr. Rustum's planned retirement and the departure of Virginia Opipare (Associate Director of Finance and Operations) in 2006, a unique opportunity became available to consolidate the responsibilities of these leadership roles into a single position to provide a more efficient and effective management of Institute operations. In early 2007, Dr. Trump recruited Jeff Walker, MBA from The Ohio State University (OSU) Comprehensive Cancer Center to a new role as the Associate Director for Administration. Mr. Walker brings more than 20 years of experience in leadership in academic/biomedical institutions, spending the last 6 years as the Associate Director for Administration of the OSU Comprehensive Cancer Center. Dr. Rustum will transition his responsibilities to Mr. Walker and remain as a Distinguished Professor and advisor to Dr. Trump and Mr. Walker. Early in 2007 Dr. Trump appointed Dr. Andrei Gudkov as the Associate Director for Basic Research replacing Dr. Michael Brattain who is leaving RPCI June, 2007. Dr. Gudkov, formerly Chairman of the Department of Molecular Genetics at the Lerner Research Institute, Cleveland Clinic Foundation, and a member of the Case Comprehensive Cancer Center, is internationally recognized for his pioneering work in gene and drug discovery. He directs a broad, highly collaborative NCI-funded program combining equally strong basic and translational components. Dr. Gudkov is also the Chair of the Cell Stress Biology Department. The 3 new senior leaders, Dr. Gudkov, Dr. Adjei, and Mr. Walker, bring fresh ideas and perspectives to the Institute as well as a wealth of scientific program development, and administrative leadership experience garnered from their involvement at other major NCI-designated cancer programs (Case Comprehensive Cancer Center, Mayo Clinic Cancer Center and the Ohio State University Comprehensive Cancer Center, respectively). Each of the Senior Leaders also plays a pivotal role in a CCSG Programs or Shared Resources. Dr. Adjei serves as Leader of the Molecular Targets and Experimental Therapeutics (MTET) and oversees Clinical Research Services, Dr. Gudkov is Leader of the Cell Stress and Biophysical Therapies (CSBT) Program, and Dr. James Marshall leads the Cancer Prevention and Population Sciences (CPPS) program. Dr. Candace Johnson is an active participant in the Prostate Program and MTET, while Dr. Trump participates in the Molecular Targets and Experimental Therapeutics Program. Mr. Walker serves as the CCSG Administrator and oversees the CCSG shared resources. All members of the Senior Leadership Team are active in the faculty recruitment process, serving as chairs or members of search committees. Further they are also involved in coordinating the EAB meetings, annual retreats, symposia/seminar series and participating in development activities. Each of these leaders is also active in national cancer research forums and well integrated into leadership and committee positions in these external arenas (ASCO, AACR, AACI, NCCN, NCI [caBIG, IRGs, parent committees]) assuring their awareness of and participation in deliberations regarding important national topics in cancer research, care and education and guaranteeing RPCI awareness of and leadership in the national trends. The Senior Leadership team interacts informally on a daily basis and meets formally on a weekly basis in the primary administrative leadership forum known as the RPCI Executive Council. Chaired by Dr. Trump, the Executive Council is the major decision-making body of the Institute, responsible for the on-going oversight of the RPCI and addressing all functional issues raised by its members. In addition, the Senior Leadership participates on the CCSG Steering Committee, a committee that meets monthly and includes the research program leaders as well as leaders of important CCSG and Institute initiatives [e.g., Imaging Development, Health Disparities]. The CCSG Steering Committee, chaired by Dr. Trump, provides a venue for strategic planning, program evaluation, membership review and approval and review of existing and proposed shared resources. Although there are several other venues where the Senior Leadership participates, it is through these two committees that primary decision-making is accomplished. There has been dramatic growth in RPCI during the last funding cycle. Over this funding cycle (2002 to 2006) the Senior Leadership team worked together to recruit more than 100 cancer investigators and clinicians, increase NCI funding by 74%, increase accruals to therapeutic investigator-initiated clinical trials and increase in out patient volume by 42% over this time period. As the number of cancer-focused basic, translational, clinical and population investigators at the RPCI have grown, four new Shared Resources have been established to support the needs of the membership with three more now in development. It is anticipated that the current Senior Leadership team will continue this successful trajectory via developing and executing longterm vision and strategic planning for the Institute.

高层领导 2007 年 3 月，在通过重大且成功的治理重组和领导 RPCI 十年之后 计划性扩张努力，David Hohn 博士从 Roswell Park Cancer 总裁兼首席执行官的职位上退休 研究所（RPCI）。 Hohn 博士在 RPCI 担任兼职高级顾问，为 高层领导负责与网络发展、设施扩展规划和特殊问题相关的问题 项目。此外，在服务 30 年后，Youcef Rustum 博士将从助理医师职位上退休。 2008 年第一季度担任核心资源总监。 2005 年，随着 Hohn 博士和 RPCI 董事会 (BOD) 开始规划领导层过渡， 有人提出特朗普博士将接替 David Hohn 博士担任总裁兼首席执行官和 CCSG PI。 董事会咨询了罗斯威尔公园领导层以及外部顾问小组的意见。基于此 根据分析，董事会为特朗普博士的过渡制定了继任计划，该计划于 2006 年 1 月 1 日开始 他被任命为研究所副所长。过渡的最后阶段按计划进行， 2007 年 4 月 1 日，特朗普博士被任命为总统兼首席执行官。值得注意的是，特朗普博士 最初于 2002 年被 RPCI 聘用，担任临床研究副总监和联合领导者 他在 RPCI 的靶向治疗项目中一直保持这一职位，直至 2006 年过渡。 特朗普在详细规划和执行这一继任计划方面的领导力和经验， 使得 RPCI 领导层能够平稳有效地过渡。 RPCI 董事 (Hohn) 和两名副董事 (Trump 和 Rustum) 的变动带来了新的高级管理人员 领导机会。随着特朗普博士于 2006 年调任研究所副所长，亚历克斯博士 Adjei 从梅奥诊所招聘并被任命为临床研究副主任 位置。他还是医学系主任。 Adjei 博士带来了丰富的科学和 癌症临床研究方面的行政领导经验，还将领导分子目标和 实验治疗计划。同样，随着 Rustum 博士的退休计划和 Virginia Opipare（财务和运营副总监）于 2006 年获得了一个独特的机会 可将这些领导角色的职责整合到一个职位中，以提供更多 研究所运营的高效和有效的管理。 2007年初，特朗普博士招募了杰夫·沃克， 俄亥俄州立大学 (OSU) 综合癌症中心 MBA 晋升为助理 行政总监。 Walker 先生带来了 20 多年的领导经验 学术/生物医学机构，过去 6 年担任该机构的行政副主任 俄勒冈州立大学综合癌症中心。 Rustum 博士将把他的职责移交给 Walker 先生并继续留任 作为特朗普博士和沃克先生的杰出教授和顾问。 2007 年初，特朗普博士任命了 安德烈·古德科夫 (Andrei Gudkov) 接替即将离职的迈克尔·布拉顿 (Michael Brattain) 博士，担任基础研究副主任 RPCI 2007 年 6 月。Gudkov 博士，勒纳大学分子遗传学系前任系主任 克利夫兰诊所基金会研究所和凯斯综合癌症中心的成员 因其在基因和药物发现方面的开创性工作而受到国际认可。他指挥了一个广泛的、高度 NCI 资助的合作项目结合了同样强大的基础和转化部分。古德科夫博士 也是细胞应激生物学系的系主任。 Gudkov 博士、Adjei 博士和 Walker 先生这三位新任高级领导人为该领域带来了新的想法和观点。 研究所以及丰富的科学项目开发​​和行政领导经验 通过参与 NCI 指定的其他主要癌症项目（案例综合 癌症中心、梅奥诊所癌症中心和俄亥俄州立大学综合癌症中心， 分别）。 每位高级领导还在 CCSG 计划或共享资源中发挥着关键作用。阿杰伊博士 担任分子靶标和实验治疗 (MTET) 的领导者并监督临床 研究服务部，Gudkov 博士是细胞应激和生物物理疗法 (CSBT) 项目的负责人， James Marshall 博士领导癌症预防和人口科学 (CPPS) 项目。坎迪斯博士 约翰逊是前列腺计划和 MTET 的积极参与者，而特朗普博士则参加 分子靶点和实验治疗计划。 Walker 先生担任 CCSG 管理员 并监督 CCSG 共享资源。高级领导团队的所有成员都积极参与 教师招聘过程，担任搜寻委员会的主席或成员。此外，他们还 参与协调 EAB 会议、年度务虚会、专题讨论会/研讨会系列并参与 发展活动。这些领导者中的每一位都积极参与国家癌症研究论坛，并且 融入这些外部领域（ASCO、AACR、AACI、NCCN、NCI [caBIG、IRG、家长委员会]）确保他们了解并参与有关以下问题的审议 癌症研究、护理和教育方面的重要国家课题，并保证 RPCI 的认识和 引领全国潮流。 高级领导团队每天进行非正式互动，并每周在办公室举行正式会议 主要行政领导论坛称为 RPCI 执行委员会。由特朗普博士担任主席 常务理事会是协会的主要决策机构，负责协会的日常监督工作 RPCI 并解决其成员提出的所有功能问题。此外，高层领导 参加 CCSG 指导委员会，该委员会每月举行一次会议，包括研究 项目领导者以及重要 CCSG 和研究所计划的领导者 [例如成像开发、 健康差异]。由特朗普博士担任主席的 CCSG 指导委员会为战略性决策提供了场所 规划、方案评估、成员审查和批准以及现有和拟议共享的审查 资源。尽管高级领导层还可以参加其他几个场所，但这是通过 这两个委员会已经完成了主要决策。 RPCI 在上一个融资周期中出现了显着增长。在此资助周期内（2002 年至 2006 年） 高级领导团队共同招募了 100 多名癌症研究人员和临床医生， 将 NCI 资助增加 74%，增加治疗研究者发起的临床试验的应计费用，并增加 在此期间，门诊量增加了 42%。随着以癌症为中心的基础、转化、 RPCI 的临床和人口研究人员不断壮大，四个新的共享资源已建立 成立的目的是为了支持会员的需求，目前还有另外三个正在开发中。预计 目前的高级领导团队将通过制定和执行长期计划来延续这一成功轨迹 研究所的愿景和战略规划。